Recent public comments by HHS officials on the Trump Administration’s agenda for lowering drug pricing shed some light on the department’s current thinking about value-based pricing for drugs.
Here’s what we’ve heard: HHS doesn’t like the idea of the US government defining the value of prescription drugs and prefers instead a market-based approach. At the same time, the...